For as good as it is, I don't understand the Reuters article about the FDA staffers disapproval of it. Seemed more like a hit job by analyst/brokers trying to get their clients in cheap before Adcom. I missed this opportunity completely by holding, need 2.17 to break even. Will be more careful with these plays till I get my head around using options. I normally short theses kind of events.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.